Home/ Stocks/ NKTR

Nektar Therapeutics

NKTR XNAS

$76.48 +2.01 (+2.74%) ▲ 15-min delayed

Open

$74.55

High

$77.00

Low

$73.18

Volume

899.2K

Market Cap

$2.48B

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 63 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$10.86M	$-44,904,000	$-1.82
FY 2025	$55.23M	$-164,076,000	$-9.73
Q3 2025	$11.79M	$-35,522,000	$-1.87
Q2 2025	$11.18M	$-41,593,000	$-2.95

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for NKTR yet. Check out our latest market news or earnings calendar.

Get NKTR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Nektar Therapeutics.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.